will now cover a medication that treats Type 1 spinal muscular atrophy (SMA), a rare neuromuscular disease affecting around 30 people in the province, most of whom are babies. Type 1 SMA is generally diagnosed within the first seven months of life, and can lead to paralysis in infants. Multiple layers of approvalDrugs seeking to be listed in Canada are approved through the Common Drug Review at the national level. Spinraza was first approved by the Common Drug Review in November 2017. Dix said some patients previously had access to the drug through a clinical trial at B.C.

Source: CBC News October 03, 2018 14:26 UTC